Stock GENO GENOVIS AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genovis AB

Equities

GENO

SE0002485979

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm
Other stock markets
 12:22:38 28/06/2024 BST 		5-day change 1st Jan Change
28.75 SEK -0.35% Intraday chart for Genovis AB +0.52% -44.71%
05-15 Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-14 Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,578 2,062 4,779 3,008 3,404 1,889 - -
Enterprise Value (EV) 1 1,563 2,018 4,698 2,935 3,281 1,780 1,761 1,744
P/E ratio 167 x 315 x 178 x 242 x 55.3 x 46.6 x 39.3 x 34.2 x
Yield - - - - - - - -
Capitalization / Revenue 26.1 x 33.8 x 51.4 x 29.4 x 21.5 x 12.3 x 9.98 x 8.54 x
EV / Revenue 25.8 x 33.1 x 50.5 x 28.7 x 20.7 x 11.6 x 9.3 x 7.88 x
EV / EBITDA 115 x 235 x 155 x 123 x 51.3 x 29.5 x 24.1 x 20.5 x
EV / FCF 196 x -121 x 115 x -618 x 59.7 x 57 x 39.8 x 44 x
FCF Yield 0.51% -0.83% 0.87% -0.16% 1.67% 1.76% 2.51% 2.27%
Price to Book - 23.7 x 41.9 x 23.9 x 17.9 x 8.51 x 7.23 x 6.2 x
Nbr of stocks (in thousands) 63,100 65,466 65,466 65,466 65,466 65,466 - -
Reference price 2 25.00 31.50 73.00 45.95 52.00 28.85 28.85 28.85
Announcement Date 05/02/20 11/02/21 08/02/22 15/02/23 15/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 60.55 61.03 93.02 102.4 158.2 153.5 189.3 221.2
EBITDA 1 13.56 8.573 30.31 23.91 63.95 60.43 73.1 84.9
EBIT 1 10.07 3.14 24.54 17.28 55.8 48.5 60.35 70.57
Operating Margin 16.62% 5.15% 26.39% 16.88% 35.27% 31.59% 31.88% 31.91%
Earnings before Tax (EBT) 1 9.667 2.149 24.6 7.996 54.85 48.53 60.5 55.9
Net income 1 9.551 6.446 24.78 11.19 61.5 40.78 49.15 43.73
Net margin 15.77% 10.56% 26.64% 10.93% 38.87% 26.56% 25.96% 19.77%
EPS 2 0.1500 0.1000 0.4100 0.1900 0.9400 0.6188 0.7334 0.8438
Free Cash Flow 1 7.971 -16.68 40.92 -4.753 54.94 31.25 44.27 39.6
FCF margin 13.16% -27.32% 43.99% -4.64% 34.72% 20.35% 23.39% 17.9%
FCF Conversion (EBITDA) 58.77% - 134.99% - 85.92% 51.71% 60.56% 46.64%
FCF Conversion (Net income) 83.46% - 165.15% - 89.34% 76.64% 90.07% 90.56%
Dividend per Share - - - - - - - -
Announcement Date 05/02/20 11/02/21 08/02/22 15/02/23 15/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 42.06 32.57 21.09 22.98 25.74 71.28 29.46 30.19 27.31 40.06 33.2 32.77 46.3
EBITDA 1 23.36 11.72 2.109 6.997 3.085 45.09 7.687 8.193 3.615 18.57 10.92 9.953 21.21
EBIT 1 21.9 10.1 0.221 4.993 1.957 43.4 5.981 5.662 0.76 15.83 8.19 6.92 18.18
Operating Margin 52.06% 31.02% 1.05% 21.73% 7.6% 60.89% 20.3% 18.76% 2.78% 39.53% 24.67% 21.12% 39.27%
Earnings before Tax (EBT) 21.83 - 0.211 5.008 -7.274 43.74 6.617 4.269 0.226 15.96 - - -
Net income 1 22.21 12.32 0.672 5.708 -7.508 43.56 15.22 3.138 -0.422 12.74 6.285 6.78 3.745
Net margin 52.8% 37.81% 3.19% 24.84% -29.17% 61.12% 51.65% 10.4% -1.55% 31.81% 18.93% 20.69% 8.09%
EPS 2 0.3500 - 0.0100 0.0900 -0.1100 0.6700 0.2300 0.0500 -0.0100 0.1900 0.7867 0.8833 0.0967
Dividend per Share - - - - - - - - - - - - -
Announcement Date 08/02/22 27/04/22 12/08/22 15/11/22 15/02/23 16/05/23 24/08/23 15/11/23 15/02/24 15/05/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 15 44.1 81.3 72.8 123 108 128 145
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 7.97 -16.7 40.9 -4.75 54.9 31.3 44.3 39.6
ROE (net income / shareholders' equity) 31% 10.5% 24.6% 16.9% 39.9% 19% 18.8% 15.4%
ROA (Net income/ Total Assets) - - - 13.8% - 12% 9.91% 12.1%
Assets 1 - - - 81 - 339.4 496.1 361.6
Book Value Per Share 2 - 1.330 1.740 1.920 2.910 3.390 3.990 4.660
Cash Flow per Share 2 - 0.0600 0.6900 - 1.030 0.5000 0.8000 0.9000
Capex 1 - 20.4 4.49 3.83 12.8 7.79 12.4 14.8
Capex / Sales - 33.48% 4.83% 3.74% 8.09% 5.08% 6.53% 6.68%
Announcement Date 05/02/20 11/02/21 08/02/22 15/02/23 15/02/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Genovis AB

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
28.85 SEK
Average target price
51.5 SEK
Spread / Average Target
+78.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
GENOVIS AB Stock Genovis AB
-44.71% 178M
BIOMÉRIEUX Stock bioMérieux
-11.08% 11.41B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-12.48% 7.4B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+31.15% 5.64B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-0.17% 5.33B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-18.68% 3.7B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+7.43% 2.58B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-64.53% 2.38B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+27.01% 2.2B
VITROLIFE AB Stock Vitrolife AB
-10.27% 2.2B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. GENO Stock
  4. Financials Genovis AB